HK1030887A1 - Treatment of bladder cancer by mycobacterium phleicell wall. - Google Patents

Treatment of bladder cancer by mycobacterium phleicell wall.

Info

Publication number
HK1030887A1
HK1030887A1 HK01101907A HK01101907A HK1030887A1 HK 1030887 A1 HK1030887 A1 HK 1030887A1 HK 01101907 A HK01101907 A HK 01101907A HK 01101907 A HK01101907 A HK 01101907A HK 1030887 A1 HK1030887 A1 HK 1030887A1
Authority
HK
Hong Kong
Prior art keywords
mycobacterium
phlei
phleicell
treatment
wall
Prior art date
Application number
HK01101907A
Other languages
English (en)
Inventor
Nigel C Phillips
Mario C Filion
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Publication of HK1030887A1 publication Critical patent/HK1030887A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK01101907A 1998-02-18 2001-03-16 Treatment of bladder cancer by mycobacterium phleicell wall. HK1030887A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7511198P 1998-02-18 1998-02-18
PCT/CA1998/001190 WO1999042113A1 (en) 1998-02-18 1998-12-22 Composition and method for the treatment of bladder cancer

Publications (1)

Publication Number Publication Date
HK1030887A1 true HK1030887A1 (en) 2001-05-25

Family

ID=22123625

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01101907A HK1030887A1 (en) 1998-02-18 2001-03-16 Treatment of bladder cancer by mycobacterium phleicell wall.

Country Status (14)

Country Link
EP (1) EP1054680B1 (xx)
JP (1) JP4426097B2 (xx)
CN (1) CN1153576C (xx)
AT (1) ATE290390T1 (xx)
AU (1) AU751667B2 (xx)
CA (1) CA2321296A1 (xx)
DE (1) DE69829316T2 (xx)
DK (1) DK1054680T3 (xx)
ES (1) ES2238780T3 (xx)
HK (1) HK1030887A1 (xx)
NZ (1) NZ506406A (xx)
PT (1) PT1054680E (xx)
RO (1) RO122992B1 (xx)
WO (1) WO1999042113A1 (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7501700A (en) * 1999-09-29 2001-04-30 Bioniche Life Sciences Inc. Method to disrupt mitochondrial function
WO2001047561A1 (en) 1999-12-28 2001-07-05 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
US20030044352A1 (en) * 2001-04-24 2003-03-06 Phillips Nigel C. Method for evaluating the efficacy of treatment with bacterial DNA and bacterial cell walls
CN101829154B (zh) * 2010-04-23 2012-12-26 广西医科大学第一附属医院 防治哮喘的药物组合物的制备方法
BR112013008727A2 (pt) * 2010-10-13 2016-06-28 Bioniche Urology Ip Inc composições de parede celular de ácido ribonucleico micobacteriano e métodos de fabricação e uso das mesmas
TR201101874A2 (tr) 2011-02-25 2011-08-22 Leyla A�An Nac�Ye Yüzeyel mesane tümorü tedavisinde kullanılabilecek mycobacterıum(mikobakteri) brumae hücre duvarı ekstreleri.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL134371A0 (en) * 1997-08-05 2001-04-30 Bioniche Life Sciences Inc Composition and method for regulating cell proliferation and cell death

Also Published As

Publication number Publication date
DE69829316D1 (de) 2005-04-14
WO1999042113A1 (en) 1999-08-26
JP2002503697A (ja) 2002-02-05
PT1054680E (pt) 2005-06-30
ES2238780T3 (es) 2005-09-01
NZ506406A (en) 2002-11-26
ATE290390T1 (de) 2005-03-15
EP1054680B1 (en) 2005-03-09
CA2321296A1 (en) 1999-08-26
RO122992B1 (ro) 2010-06-30
JP4426097B2 (ja) 2010-03-03
AU751667B2 (en) 2002-08-22
DE69829316T2 (de) 2006-04-13
CN1153576C (zh) 2004-06-16
CN1290171A (zh) 2001-04-04
DK1054680T3 (da) 2005-06-27
EP1054680A1 (en) 2000-11-29
AU1746599A (en) 1999-09-06

Similar Documents

Publication Publication Date Title
DK0762898T3 (da) Cyclodextrinsystem til levering af oligonukleotider til celler
IL147017A0 (en) TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES
WO2001024763A3 (en) Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
AU4221399A (en) Human cd45+ and/or fibroblast + mesenchymal stem cells
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
MY121548A (en) Compounds and methods for the treatment of cancer
AU2915800A (en) Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
SI1297013T1 (sl) Uporaba TACI kot protitumorskega sredstva
IL180924A0 (en) Method for regulating cell proliferation and cell death
WO2001006990A3 (en) Use of etodolac to treat cancer
HK1030887A1 (en) Treatment of bladder cancer by mycobacterium phleicell wall.
MY121046A (en) Substituted bisindolylmaleimides for the inhibition of cell proliferation
DE60120162D1 (en) Polyamin-analoge als cytotoxische wirkstoffe
AU2289400A (en) 6-arylphenanthridines with pde-iv inhibiting activity
AU2107700A (en) Phenanthridine-n-oxides with pde-iv inhibiting activity
WO2004009112A8 (en) Use of urease for inhibiting cancer cell growth
AU7074298A (en) Activated iododerivatives for the treatment of cancer and aids
EP1165106B8 (en) Composition and method for inducing apoptosis in prostate cancer cells by m-dna and mcc
PL331104A1 (en) Therapeutic application of bam (cd40l) technology in treating diseases related to smooth muscles
WO2005032595A3 (en) Methods and compositions for the inhibition of stat5 in prostate cancer cells
EP0799835A3 (en) Anti-fibroblast growth factor-8 monoclonal antibody
PT1135164E (pt) Metodo para o tratamento de inflamacao
Hashimoto et al. DNA Strand Scissions by Hydroxamic Acids-Copper (II) Ion under Aerobic Conditions.
ATE276766T1 (de) Chemotherapeutische zusammensetzung und verfahren

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20131222